Injection pens for weight loss: what the clinical evidence tells us

What the trial data established, and why it matters for anyone considering a pen

The clearest starting point is the trial record. The SURMOUNT-1 study, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and no diabetes to tirzepatide or placebo over 72 weeks. At the 15 mg maintenance dose, average body-weight reduction reached around 20 to 21 percent, figures that had not been seen with any previous licensed injection. Semaglutide's STEP 1 trial reported approximately 15 percent average reduction over 68 weeks at 2.4 mg. Those numbers come from placebo-controlled, peer-reviewed studies involving thousands of participants, which is why NICE drew on them when recommending both medicines for eligible adults.

What the trials also established is that results accumulate gradually. Neither pen produces rapid weight loss in the first few weeks. Treatment typically begins at a low, tolerability dose (2.5 mg for tirzepatide) with the prescriber stepping up the dose roughly every four weeks as the body adjusts. The early weeks are about settling the system, not shifting weight. Patients who understood that going in tended to find the process more manageable, according to what our clinical team consistently hears in practice.

Weight loss in the trials was also accompanied by reduced-calorie diets and increased physical activity, context that matters. The pen supports those changes; it does not replace them. NICE's appraisal of tirzepatide (TA1026) makes this explicit, recommending it only alongside lifestyle intervention.

How the pens actually deliver the medicine, the mechanics worth knowing

Mounjaro's pre-filled KwikPen contains four weekly doses. You dial to the correct dose, press the pen against the skin of your abdomen, thigh or upper arm, press the button, and hold for several seconds until the dose is confirmed. Each injection takes a matter of moments. Rotating the site each week (moving around the abdomen, for example, rather than always the same spot) reduces local skin reactions over time. Full step-by-step technique is covered in the patient information leaflet and on the injection technique guide on this site.

Wegovy uses a separate pre-filled single-use pen for each weekly dose, auto-injecting when pressed against the skin. The needle is covered before and after use, which many people find reassuring if they are nervous about injections. Both pens must be refrigerated between 2°C and 8°C; the patient leaflet specifies exactly how long either can remain at room temperature during travel, and that is the document to follow rather than any general guidance.

Needles on Mounjaro's pen are fixed. Some clinical setups advise using a fresh needle for each injection, our FAQs page covers practical questions about pen use and storage in more detail. Disposing of used pens and needles correctly matters too: a 1-litre sharps container keeps used materials safely contained until your local pharmacy or council collection service takes them.

Who the licensed pens are designed for, and the clinical picture behind eligibility

Both pens are licensed for adults, not under-18s. The licensed eligibility threshold for private prescribing is a BMI of 30 or above, or 27 or above when at least one weight-related condition is present, conditions such as high blood pressure, type 2 diabetes, obstructive sleep apnoea, or high cholesterol. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance.

NHS access follows stricter criteria phased in over time. From June 2025, tirzepatide became available through primary care for adults with a BMI of 40 or above and four or more of a defined set of weight-related conditions. A second cohort, covering BMI 35 to 39.9 with four or more qualifying conditions, opened in June 2026. Many people do not yet meet those thresholds or face long specialist waiting lists, which is why regulated private routes exist. You can read more about how weight-loss injections are accessed in the UK and compare NHS and private pathways.

BMI alone is never the whole picture. A prescriber weighs medical history, current medicines, contraindications and the reasons someone is seeking treatment before approving any pen. Women using oral contraceptives starting tirzepatide are advised to add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because the pill's absorption may be reduced; this is documented in NHS England's guidance on weight-management injections. Pregnancy, breastfeeding, and trying to conceive are contraindications for both pens; the prescriber will ask.

Side effects: what the evidence shows and when to act quickly

The most common side effects reported in the trials and in clinical practice are gastrointestinal: nausea, loose stools, constipation, reflux and burping. These are most noticeable in the days after starting or after a dose increase and often settle within one to two weeks as the body adapts. Eating smaller portions, staying well hydrated and avoiding very fatty or spicy meals during adjustment tends to help, something prescribers mention in first-week check-ins more often than any other single piece of advice.

Less common but more serious: acute pancreatitis has been identified as a known side effect. The MHRA issued a Drug Safety Update in January 2026 specifically addressing GLP-1 medicines and pancreatitis, advising anyone experiencing severe, persistent stomach pain (particularly pain that radiates towards the back, with or without vomiting) to seek urgent medical attention. That is a situation not to manage at home. You can report any suspected side effect directly at the MHRA's Yellow Card scheme, which also accepts reports of suspect or counterfeit medicines.

For anyone weighing up which pen might suit them, or thinking about how to access weight-loss injections safely, a structured clinical consultation is the right first step. At nume, a GPhC-registered Independent Prescriber reviews every consultation the same day, a real clinician reading your answers, not an automated process. If you are clinically suitable and order before midday on a weekday, your pen is dispatched that day and arrives with DPD the next working morning. Start your free consultation to find out whether a weight loss injection pen is right for you, whether you are exploring a Mounjaro injection for weight loss or want a broader overview of every available weight loss injection option.